CONCORD, Mass., Nov. 1, 2012 /PRNewswire/ -- Parios Regenerative Sciences, Inc., a privately held medical device company specializing in the development of biomaterials for skin repair and regeneration, has entered into a comprehensive license agreement with Brown University, licensing exclusive rights to a proprietary organic nanotechnology for use in dermatological applications. The nanotechnology, Oderm, has clinical relevance in cosmetic skin rejuvenation, dermatological applications, and advanced wound care.
“Our agreement with Brown is a significant milestone for Parios,” stated Mark Johanson, President and Chief Executive Officer. “The Oderm technology shows great promise in advancing the field of skin regeneration for both aesthetic and wound care applications. We are committed to the commercial and clinical success of this novel skin care product.”
Under the terms of the agreement, Parios has obtained an exclusive license to a platform of intellectual property and technologies co-developed by Dr. Thomas Webster, former associate professor of engineering at Brown.
“We are enthusiastic to have partnered with such an experienced and accomplished team at Parios,” said Katherine Gordon, Managing Director of the Brown University Technology Ventures Office, “and look forward to successful development of the product.”
The Oderm biomaterial consists of organic nanomolecules that self-assemble into structures resembling collagen a major component of skin. Using these organic structures to replace degenerated or damaged skin encourages the growth of natural tissue. The company’s goal is to provide off-the-shelf materials that regenerate healthy and functional tissue and offer a repair that lasts the life of the patient.
About Parios Regenerative Sciences, Inc.
Parios is a privately held company located in Concord, MA focused on the growing market of skin tissue regeneration. The company is developing the Oderm product line to compete in the non-invasive skin care market, by offering injectable and topical solutions to stimulate collagen regrowth. Current products are in the preclinical phase of development. With Oderm and other advanced biomaterials in the pipeline, Parios offers a modern alternative to existing skin repair therapies.
SOURCE Parios Regenerative Sciences, Inc.
